Gonorrhoea is the second most common bacterial STI worldwide.[3]World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. 2016 [internet publication].
http://www.who.int/reproductivehealth/publications/rtis/gonorrhoea-treatment-guidelines/en
The World Health Organization estimated that there were 78 million new cases of gonorrhoea in 2012 among those aged 15 to 49 years worldwide, with a global incidence rate of 19 per 1000 women and 24 per 1000 men.[3]World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. 2016 [internet publication].
http://www.who.int/reproductivehealth/publications/rtis/gonorrhoea-treatment-guidelines/en
The Western Pacific and African regions had the highest prevalence of gonorrhoea.[3]World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. 2016 [internet publication].
http://www.who.int/reproductivehealth/publications/rtis/gonorrhoea-treatment-guidelines/en
In the US, gonorrhoea is the second most commonly reported communicable disease, and the number of cases has shown a sustained increase over the past 10 years.[4]Centers for Disease Control and Prevention. Sexually transmitted infections surveillance, 2022: national overview of STIs, 2022. Jan 2024 [internet publication].
https://www.cdc.gov/std/statistics/2022/overview.htm
During 2021 and 2022, however, rates of reported gonorrhoea decreased among both men (5.4%) and women (14.5%), although these years coincide with the COVID-19 pandemic, which introduced uncertainty and difficulty in interpreting STI surveillance data.[4]Centers for Disease Control and Prevention. Sexually transmitted infections surveillance, 2022: national overview of STIs, 2022. Jan 2024 [internet publication].
https://www.cdc.gov/std/statistics/2022/overview.htm
In 2022, the gonorrhoea rate in the US was 194.4 cases per 100,000.[4]Centers for Disease Control and Prevention. Sexually transmitted infections surveillance, 2022: national overview of STIs, 2022. Jan 2024 [internet publication].
https://www.cdc.gov/std/statistics/2022/overview.htm
The southern US continues to have the highest rates in the country. Rates continue to be highest among certain groups, such as men who have sex with men, and black people. Rates also continue to be higher in men than in women. The highest rates in men and women are seen in the 20 to 24 years age group.[4]Centers for Disease Control and Prevention. Sexually transmitted infections surveillance, 2022: national overview of STIs, 2022. Jan 2024 [internet publication].
https://www.cdc.gov/std/statistics/2022/overview.htm
Rising rates of gonorrhoea have also been seen in England.[5]Public Health England. Sexually transmitted infections and screening for chlamydia in England, 2019. Sep 2020 [internet publication].
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/914184/STI_NCSP_report_2019.pdf
Many of those infected with gonorrhoea also have co-infections. A cross-sectional study of new patients attending King’s College Hospital (London) with either gonorrhoea or chlamydia found that 24.2% (124/512) of heterosexual men and 38.5% (136/335) of women with gonorrhoea also had chlamydia.[6]Creighton S, Tenant-Flowers M, Taylor CB, et al. Co-infection with gonorrhoea and chlamydia: how much is there and what does it mean? Int J STD AIDS. 2003 Feb;14(2):109-13.
http://www.ncbi.nlm.nih.gov/pubmed/12662389?tool=bestpractice.com
High rates of antimicrobial resistance to penicillin, tetracycline, and fluoroquinolones have been reported from the Gonococcal Isolate Surveillance Project, and there is concern about the potential of reduced susceptibility to extended-spectrum cephalosporins and macrolides.[7]Centers for Disease Control and Prevention. Gonococcal isolate surveillance project (GISP). 30 August 2021 [internet publication].
http://www.cdc.gov/std/gisp
Rare isolates have also been found with reduced susceptibility to cephalosporins and azithromycin, which has led to increased vigilance for antimicrobial resistance and updated treatment guidance.